Academic Accomplishments 2016
(Inova authors bolded)

ORIGINAL RESEARCH MANUSCRIPTS


REVIEWS


**EDITORIALS**

2. **King CS, Nathan SD.** “Should all patients with IPF, even those with more than moderate impairment, be treated with nintedanib or pirfenidone?” YES. Chest. 2016;150(2):273-275

**BOOK CHAPTERS AND BOOKS**

1. **King CS, Nathan SD.** Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For Pulmonary Hypertension and Interstitial lung disease. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
2. **Shlobin OA, Nathan SD.** Rare ILD and PH. For Pulmonary Hypertension and Interstitial lung disease. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.

**ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS**

5. **Nathan SD,** Baseline characteristics of patients enrolled in a prospective study of Riociguat for pulmonary hypertension associated with Idiopathic Interstitial Pneumonia (RISE-IIP Study). Presented at ATS 2016 May 16th, 2016, San Francisco.


24. Nathan SD, Stayrrook SA, King C, Weir N, Ahmad SA, Shlobin OA, Brown AW. Residual volume-

PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS
5. “Xenotransplantation: Comparison with Human Psychosocial Selection Criteria” Jane Harrison, LCSW, CCTSW; Society for Transplant Social Work, San Diego, California. 10/8/16
10. PH in ILD (session chair). 2016 ISHLT, Washington, DC. Oksana Shlobin